Monday 5 January 2015

Cempra's lead oral antibiotic meets main goal in late-stage trial

By Natalie Grover (Reuters) - Cempra Inc moved a step closer to approval of its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial. The drug is a next-generation version of a class of oft-prescribed antibiotics called macrolides, which are used to fight pathogens that cause community-acquired bacterial pneumonia (CAPB). CAPB is the leading cause of death emanating from an infection and is characterized by shortness of breath, cough and fever, with about 5-10 million cases in the United States per year. ... via Health News Headlines - Yahoo News Read More Here..

No comments:

Post a Comment